This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

GSK Keen to Keep Some Emerging Markets Drugs

Stocks in this article: GSK BX PTX

LONDON (The Deal) -- The U.K.'s GlaxoSmithKline (GSK - Get Report) will probably keep emerging-markets rights to some of the nearly 50 established drugs it has begun shopping after last year's spinoff of the products into a separate unit which had 2013 sales of about £3.8 billion ($6.4 billion).

People familiar with the situation said sales information has gone out to potential bidders including Blackstone Group (BX - Get Report), Kohlberg Kravis Roberts and Advent International. Whether the buyout firms will participate in the bidding was unclear, with one source saying it was too early to make a decision.

The British company has already sold thrombosis and migraine treatments in separate deals, and one person familiar with the situation sees GlaxoSmithKline's established products portfolio, or EPP, as most likely to be sold in pieces. The company, which is reportedly advised by Lazard, is shopping assets including anti-depressant Seroxat and malaria treatment Malarone.

The London pharmaceuticals company has begun reporting results from the EPP separately after announcing the spinoff plans in April 2013. First-quarter EPP sales were £814 million, a decline of 11% year-on-year, and operating profit was £485 million, down 12%.

Just over half of the unit's revenue comes from Europe and the U.S., where GlaxoSmithKline would look to sell rights to the largely off-patent drugs.

The U.K.'s No. 1 drugmaker wants to focus on its vaccine business, where it is the market leader as well as consumer healthcare and treatments for respiratory disorders and HIV.

In April, it boosted its vaccine and OTC healthcare business through deals with Switzerland's Novartis, which at the same time agreed to pay $16 billion for the London company's oncology business, minus the rights to products under development. The vaccine business purchase excluded Novartis' flu vaccine. The Novartis deals would have added £1.3 billion to GlaxoSmithKline's £26.9 billion in 2013 revenue, the British group said at the time.

GlaxoSmithKline closed £2.5 billion of disposals last year. In September, it agreed to sell its Lucozade and Ribena drink brands to Japan's Suntory Beverage & Food for £1.35 billion and to sell its Arixtra and Fraxiparine thrombosis treatments to South Africa's Aspen Pharmacare Holdings for £700 million.

Earlier this month, Pernix Therapeutics Holdings (PTX - Get Report) of Morristown, N.J., agreed to buy the U.S. rights to GlaxoSmithKline's migraine treatment Treximet for $250 million up front.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs